News Focus
News Focus
Replies to #52633 on Biotech Values
icon url

DewDiligence

09/21/07 1:20 PM

#52647 RE: Biopharm investor #52633

>The only question is what the generic firms will get in return for paying these fees.<

What kind of agreed turnaround time for ANDA’s is being considered?